Aquestive Therapeutics Inc., a pharmaceutical company focused on advancing medicines through innovative science and delivery technologies, announced upcoming presentations of positive data from pharmacokinetic and pharmacodynamic studies on Anaphylm™ (epinephrine) Sublingual Film. These findings, concerning the treatment of severe allergic reactions including anaphylaxis, will be showcased at the Center for Food Allergy and Asthma Research (CFAAR) Food Allergy Summit in Chicago from June 27-29, 2025. The data, previously presented at the 2025 AAAAI Annual Meeting, highlights Anaphylm as potentially the first orally delivered epinephrine option in the United States, pending FDA approval. Poster presentations will cover the physicochemical properties of Anaphylm under extreme conditions and its rapid pharmacokinetic and pharmacodynamic responses, scheduled for June 28 from 5:00 PM to 7:30 PM CST. Abstracts are accessible on the company's website in the Scientific Events section.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.